BioCentury | Jan 8, 2016
Financial News

Diagnostics plays Guardant, Exosome close private rounds

...said it closed a series B round with $60 million. Investors included Forbion Capital Partners, NGN Capital...
BioCentury | Sep 7, 2015
Financial News

Exosome Diagnostics financial update

...bringing the total raised in the round to $44.6 million. Existing investors Forbion Capital Partners; NGN Capital...
BioCentury | Mar 17, 2014
Finance

Tuned up for cash flow

...Also new to the syndicate were Tiger Partners; CD Ventures; and Monashee Capital. Existing investors NGN Capital...
BioCentury | Mar 17, 2014
Financial News

Exosome Diagnostics completes venture financing

...agent: Leerink Partners Investors: Qiagen N.V. ; Arcus Ventures; Tiger Partners; CD Ventures; Monashee Capital; NGN Capital...
BioCentury | Mar 12, 2014
Financial News

Exosome Diagnostics raises $27 million in series B

...New investors Tiger Partners; CD Ventures; and Monashee Capital also participated, along with existing investors NGN Capital...
BioCentury | May 9, 2011
Emerging Company Profile

ACT: ACTing selectively

...the 2008 deal with Bayer, ACT raised $12 million in a series A round from NGN Capital...
...University collaborators: None Corporate partners: None Number of employees: 6 Funds raised: $18 million Investors: NGN Capital...
BioCentury | Jun 14, 2010
Emerging Company Profile

Exosome: Bountiful harvest

...than glioblastoma. Exosome raised $20 million last month in a series A round co-led by NGN Capital...
...San Diego Corporate partners: Not disclosed Number of employees: 15 Funds raised: $22 million Investors: NGN Capital...
BioCentury | May 31, 2010
Financial News

Noxxon completes venture financing

...Business: Autoimmune, Cancer, Endocrine Date completed: 5/27/10 Type: Venture financing Raised:€33 million ($41.2 million) Investors: NGN Capital...
BioCentury | May 28, 2010
Financial News

Noxxon raises EUR 33 million

...raised EUR 33 million ($41.2 million) in a series D round led by new investor NGN Capital...
...diabetic nephropathy and NOX-A12 for autologous hematopoietic stem cell transplantation in patients with hematological malignancies. NGN Capital's...
BioCentury | May 17, 2010
Company News

Exosome Diagnostics board of directors update

...Diagnostics Inc. , New York, N.Y. Business: Diagnostic Appointed: Peter Johann, managing general partner at NGN Capital...
...Geert-Jan Mulder, general partner at Forbion Capital Partners; and Georg Nebgen, managing general partner at NGN Capital WIR...
Items per page:
1 - 10 of 45
BioCentury | Jan 8, 2016
Financial News

Diagnostics plays Guardant, Exosome close private rounds

...said it closed a series B round with $60 million. Investors included Forbion Capital Partners, NGN Capital...
BioCentury | Sep 7, 2015
Financial News

Exosome Diagnostics financial update

...bringing the total raised in the round to $44.6 million. Existing investors Forbion Capital Partners; NGN Capital...
BioCentury | Mar 17, 2014
Finance

Tuned up for cash flow

...Also new to the syndicate were Tiger Partners; CD Ventures; and Monashee Capital. Existing investors NGN Capital...
BioCentury | Mar 17, 2014
Financial News

Exosome Diagnostics completes venture financing

...agent: Leerink Partners Investors: Qiagen N.V. ; Arcus Ventures; Tiger Partners; CD Ventures; Monashee Capital; NGN Capital...
BioCentury | Mar 12, 2014
Financial News

Exosome Diagnostics raises $27 million in series B

...New investors Tiger Partners; CD Ventures; and Monashee Capital also participated, along with existing investors NGN Capital...
BioCentury | May 9, 2011
Emerging Company Profile

ACT: ACTing selectively

...the 2008 deal with Bayer, ACT raised $12 million in a series A round from NGN Capital...
...University collaborators: None Corporate partners: None Number of employees: 6 Funds raised: $18 million Investors: NGN Capital...
BioCentury | Jun 14, 2010
Emerging Company Profile

Exosome: Bountiful harvest

...than glioblastoma. Exosome raised $20 million last month in a series A round co-led by NGN Capital...
...San Diego Corporate partners: Not disclosed Number of employees: 15 Funds raised: $22 million Investors: NGN Capital...
BioCentury | May 31, 2010
Financial News

Noxxon completes venture financing

...Business: Autoimmune, Cancer, Endocrine Date completed: 5/27/10 Type: Venture financing Raised:€33 million ($41.2 million) Investors: NGN Capital...
BioCentury | May 28, 2010
Financial News

Noxxon raises EUR 33 million

...raised EUR 33 million ($41.2 million) in a series D round led by new investor NGN Capital...
...diabetic nephropathy and NOX-A12 for autologous hematopoietic stem cell transplantation in patients with hematological malignancies. NGN Capital's...
BioCentury | May 17, 2010
Company News

Exosome Diagnostics board of directors update

...Diagnostics Inc. , New York, N.Y. Business: Diagnostic Appointed: Peter Johann, managing general partner at NGN Capital...
...Geert-Jan Mulder, general partner at Forbion Capital Partners; and Georg Nebgen, managing general partner at NGN Capital WIR...
Items per page:
1 - 10 of 45